The optimal clinical management of women with the BRCA1/2 mutations depends on accurate age-specific cancer risk estimates, which can then be used to estimate the absolute risk reduction in preventative strategies and inform decisions regarding the age at which to start surveillance [46,59]. The gene discussed is BRCA1; the disease is cancer.